Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody

[1] Sato S(2005)Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis Arthritis Rheum 52 1571-6

[2] Hirakata M(2016)Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis Arthritis Care Res (Hoboken) 68 689-94

[3] Kuwana M(2019)Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease Eur J Dermatol 29 511-7

[4] Suwa A(2007)The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease Am J Clin Pathol 127 237-47

[5] Inada S(2015)Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis Respir Med 109 1174-80

[6] Mimori T(2019)The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients Rheumatology (Oxford) 58 786-91

[7] Moghadam-Kia S(2022)Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses Clin Exp Rheumatol 40 304-8

[8] Oddis CV(2020)Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases Neurology 95 e70-e8

[9] Sato S(2020)239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018 Neuromuscul Disord 30 70-92

[10] Kuwana M(2004)X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 7252-9

[1] Sato S(2005)Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis Arthritis Rheum 52 1571-6

[2] Hirakata M(2016)Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis Arthritis Care Res (Hoboken) 68 689-94

[3] Kuwana M(2019)Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease Eur J Dermatol 29 511-7

[4] Suwa A(2007)The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease Am J Clin Pathol 127 237-47

[5] Inada S(2015)Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis Respir Med 109 1174-80

[6] Mimori T(2019)The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients Rheumatology (Oxford) 58 786-91

[7] Moghadam-Kia S(2022)Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses Clin Exp Rheumatol 40 304-8

[8] Oddis CV(2020)Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases Neurology 95 e70-e8

[9] Sato S(2020)239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018 Neuromuscul Disord 30 70-92

[10] Kuwana M(2004)X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization Clin Cancer Res 10 7252-9